An Alzheimer’s blood test can help determine whether someone may be eligible for Leqembi or Kisunla, but it usually cannot establish eligibility by itself. These anti-amyloid drugs are intended for people with early symptomatic Alzheimer’s disease—mild cognitive impairment or mild dementia—with confirmed amyloid pathology. For example, a person with gradually worsening memory and a positive amyloid-related blood test may be referred for additional evaluation, but treatment would not begin until the clinician also reviews cognitive testing, medical history, brain imaging, and safety risks.
Blood biomarkers can make the evaluation faster and less invasive by estimating whether Alzheimer’s-related amyloid changes are present. A clearly negative result may make amyloid-targeting treatment less likely to help, while a positive result may support further assessment or, in some clinical settings, contribute to confirmation. Results near a test’s cutoff are less dependable, and clinicians may still require an amyloid PET scan or cerebrospinal fluid analysis before prescribing Leqembi or Kisunla.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Can an Alzheimer’s Blood Test Determine Eligibility for Leqembi or Kisunla?
- How Blood Biomarkers Fit Into Amyloid Confirmation
- Clinical Stage, Symptoms, and Cognitive Testing
- What to Expect During a Leqembi or Kisunla Eligibility Evaluation
- ARIA, Blood Thinners, and Other Safety Issues
- Positive, Negative, and Indeterminate Blood Test Results
- Questions to Bring to the Memory Specialist
- Frequently Asked Questions
Can an Alzheimer’s Blood Test Determine Eligibility for Leqembi or Kisunla?
A blood test answers only one part of the eligibility question: whether the person is likely to have the biological changes associated with Alzheimer’s disease. Tests may measure phosphorylated tau, beta-amyloid ratios, or combinations of biomarkers. Some are designed to identify amyloid pathology, while others estimate the likelihood that Alzheimer’s disease is causing a person’s symptoms. These purposes are related but not interchangeable. Eligibility also depends on the person’s clinical stage. Leqembi and Kisunla were studied in people with mild cognitive impairment or mild dementia due to Alzheimer’s disease, not in people with moderate or severe dementia.
A positive biomarker in someone who remains cognitively normal does not automatically make that person a treatment candidate. Likewise, a positive result in someone with advanced dementia does not show that the drug’s benefits and risks apply at that stage. Consider two people with similar positive blood results. One is still independent in daily activities but repeatedly forgets recent conversations and has objective memory impairment on testing. The other needs extensive help dressing, bathing, and eating because of advanced dementia. The first person may fit the early-disease population considered for treatment; the second generally would not, even though both may have Alzheimer’s amyloid pathology.
How Blood Biomarkers Fit Into Amyloid Confirmation
Amyloid confirmation has traditionally involved an amyloid PET scan or analysis of cerebrospinal fluid obtained through a lumbar puncture. A blood test is simpler to collect and may be easier to repeat, but its role depends on the particular assay, its regulatory status, its validated cutoff values, and the treatment center’s protocol. A result from a general laboratory panel should not be assumed to provide the same evidence as a test specifically validated for detecting Alzheimer’s amyloid pathology. blood tests can be especially useful as triage tools.
A clinician may use a negative result to investigate other causes of memory loss, such as medication effects, sleep apnea, depression, thyroid disease, vitamin deficiency, vascular injury, or another neurodegenerative disorder. A strongly positive result may justify moving promptly to an Alzheimer’s specialty evaluation or confirmatory testing. The limitation is that no biomarker cutoff perfectly separates people with and without brain amyloid. Kidney disease, other medical conditions, differences among laboratory methods, and values close to the decision threshold can complicate interpretation. An indeterminate or borderline result should not be treated as a diagnosis, and patients should be wary of consumer-facing reports that label risk as “high” without explaining whether the test has been validated for treatment selection.
Clinical Stage, Symptoms, and Cognitive Testing
A treatment evaluation begins with symptoms and function, not a laboratory number. Clinicians usually document a history of cognitive decline, perform standardized cognitive testing, and assess how well the person handles complex activities such as managing finances, taking medications, preparing meals, driving, and keeping appointments. Information from a family member or other knowledgeable person can reveal changes that a brief office visit misses. For example, a retired accountant may score reasonably well on a short screening test yet have begun paying the same bill several times and missing tax deadlines.
That functional history may support a diagnosis of mild cognitive impairment or mild dementia when interpreted alongside more detailed testing. Conversely, a low screening score during delirium, severe depression, or an acute illness may not represent Alzheimer’s disease and should not be used alone to justify anti-amyloid treatment. A person can also have more than one cause of cognitive impairment. Alzheimer’s pathology may coexist with strokes, Lewy body disease, traumatic brain injury, or substantial vascular disease. A positive blood biomarker can identify Alzheimer’s biology without proving that it is the only—or even the main—reason for the person’s current disability.
What to Expect During a Leqembi or Kisunla Eligibility Evaluation
A practical evaluation generally includes a detailed medical history, neurological examination, cognitive and functional assessment, amyloid testing, medication review, and a recent brain MRI. The MRI looks for findings that may raise treatment risk, including prior brain bleeding, certain small hemorrhages, superficial siderosis, significant swelling, or extensive vascular injury. The exact exclusions and precautions should be checked against the current prescribing information and the treatment program’s protocol. Clinicians may also discuss APOE genotyping.
People who carry the APOE ε4 variant—especially those with two copies—have a higher risk of amyloid-related imaging abnormalities, commonly called ARIA. APOE status does not simply produce an eligible-or-ineligible answer; it helps the patient and clinician weigh potential benefit against the chance of brain swelling or bleeding. The tradeoff is that blood testing is convenient, while treatment assessment remains demanding. A blood draw may take minutes, but Leqembi and Kisunla require intravenous infusions and scheduled MRI monitoring. Leqembi and Kisunla also use different dosing schedules and treatment approaches, so eligibility for anti-amyloid therapy does not automatically establish which drug is the better choice for a particular person.
ARIA, Blood Thinners, and Other Safety Issues
ARIA is one of the most important safety considerations with anti-amyloid antibodies. It can appear as temporary brain swelling or as small areas of bleeding seen on MRI. Many cases cause no symptoms, but possible warning signs include headache, confusion, dizziness, visual changes, nausea, difficulty walking, weakness, seizures, or other sudden neurological changes. Symptoms suggesting stroke or serious ARIA require urgent medical evaluation rather than waiting for the next infusion appointment. Anticoagulants and other drugs that affect clotting require careful review because intracranial bleeding is a concern.
A person with atrial fibrillation who takes an anticoagulant, for example, may face a different risk calculation than someone taking no blood-thinning medication. Patients should not stop an anticoagulant or aspirin on their own; doing so can increase the risk of stroke, heart attack, or another serious event. Other practical barriers can affect candidacy even when the blood test is positive. The person must be able to attend infusions, complete follow-up MRIs, report symptoms promptly, and maintain reliable coordination with the treatment team. Severe claustrophobia, an MRI-incompatible implanted device, unstable medical illness, or inability to obtain required monitoring may delay or prevent treatment. A positive Alzheimer’s blood test does not override these safety limitations.
Positive, Negative, and Indeterminate Blood Test Results
A positive result raises the likelihood of Alzheimer’s pathology but must be matched to the person’s symptoms and clinical stage. A negative result lowers that likelihood, although its meaning depends on the assay and the person being tested.
An indeterminate result usually means that the value falls into a range where the test cannot classify amyloid status with sufficient confidence. For example, a memory clinic may send a patient with an indeterminate blood result for an amyloid PET scan or lumbar puncture rather than treating the result as positive. If confirmatory testing is negative, Leqembi or Kisunla would generally not be appropriate because the required amyloid target has not been established.
Questions to Bring to the Memory Specialist
Patients and caregivers should ask for the exact name of the blood test, what biomarker it measures, whether it is intended to identify brain amyloid, and how positive, negative, and indeterminate categories are defined. They can also ask whether the clinic accepts that test as amyloid confirmation or requires PET imaging or cerebrospinal fluid analysis.
It is also useful to bring an updated medication list, prior brain-imaging reports, a timeline of cognitive changes, and examples of altered daily function. A note that says “missed four medication doses this month and became lost driving to a familiar store,” for instance, gives the clinician more actionable information than a general statement that memory is worsening.
Frequently Asked Questions
Does a positive Alzheimer’s blood test mean I can start Leqembi or Kisunla?
No. It may support evidence of Alzheimer’s pathology, but the clinician must also confirm early symptomatic disease and assess MRI findings, medications, medical conditions, and the person’s ability to complete monitoring.
Can a blood test replace an amyloid PET scan or lumbar puncture?
Sometimes, depending on the specific test, its validated use, current prescribing requirements, and the treatment center’s protocol. Borderline or conflicting results often require PET imaging or cerebrospinal fluid testing.
Can someone without memory symptoms receive these drugs after a positive blood test?
A positive biomarker alone does not establish treatment eligibility. Leqembi and Kisunla are used for early symptomatic Alzheimer’s disease, and their established treatment populations do not simply include everyone with detectable amyloid.
What happens if the blood test is negative?
The clinician may investigate other causes of cognitive symptoms or order additional Alzheimer’s testing when clinical suspicion remains high. The reliability of a negative result depends on the assay and the clinical circumstances.
Is APOE testing the same as an Alzheimer’s blood biomarker test?
No. APOE testing identifies a genetic variant associated with Alzheimer’s risk and ARIA risk; it does not directly confirm brain amyloid. Amyloid-related blood biomarkers measure proteins or protein ratios associated with Alzheimer’s pathology.
Why is an MRI needed if the blood test is positive?
The blood test addresses Alzheimer’s biology, while MRI evaluates structural brain disease and bleeding-related risks. MRI is also used during treatment to monitor for ARIA.
